PET/MRI Dual-Modality Tumor Imaging Using Arginine-Glycine-Aspartic (RGD)–Conjugated Radiolabeled Iron Oxide Nanoparticles

Lee, Ha Young; Li, Zibo; Chen, Kai; Hsu, Andrew R.; Xu, Chen; Xie, Jin; Sun, Shouheng; Chen, Xiaoyuan

doi:10.2967/jnumed.108.051243

Cited by 501 publications

(405 citation statements)

References 28 publications

Supporting

Mentioning

395

Contrasting

Unclassified

Order By: Relevance

“…There is a great deal of interest in developing multimodality probes for molecular imaging (1)(2)(3)(4). The combination of several imaging techniques such as nuclear imaging (NI), MRI, and optical imaging represents complementary imaging information with potential utility in diagnosis.…”

mentioning

confidence: 99%

Superparamagnetic iron oxide nanoparticles as a dual imaging probe for targeting hepatocytes in vivo

Lee

Jeong

Kim

et al. 2009

Magnetic Resonance in Med

View full text Add to dashboard Cite

Hepatocyte-specific targeting agents are useful for evaluation of the hepatocytic function and the monitoring of disease progress. Superparamagnetic iron oxide nanoparticles (SPION) bearing terminal galactose groups exhibit a high affinity for the asialoglycoprotein receptor on the hepatocyte surface. In this study, we synthesized and characterized the dual probe SPION detectable by both nuclear and MR imaging modality for specifically targeting hepatocytes in vivo. SPION with 12-nm diameter were functionalized with dopamine. Surface modification of the SPION was performed to target asialoglycoprotein receptor on hepatocytes, using lactobionic acid. Transmission electron microscope images demonstrated that SPION displayed highly uniform characteristics in terms of both particle size and shape. The X-ray diffraction pattern of SPION revealed a nanocrystal structure of magnetite. To radiolabel the magnetite with 99m Tc, diethylenetriaminepentaacetic acid was conjugated to unreacted functional groups of dopamine. 99m Tc-labeled lactobionic acid-SPION showed high accumulation in liver, with 38.43 ؎ 6.45% injected dose per gram. In MR imaging, the reduction of the T 2 signal in the liver by lactobionic acid-SPION was approximately 50.8 ؎ 7.3%. Competition studies and transmission electron microscope images of liver tissues demonstrated that the lactobionic acid-SPION were localized in hepatocytes. Therefore, the lactobionic acid-SPION may be used as a hepatocyte-targeted dual contrast agent for both nuclear and MR imaging.

show abstract

mentioning

confidence: 99%

Superparamagnetic iron oxide nanoparticles as a dual imaging probe for targeting hepatocytes in vivo

Lee

Jeong

Kim

et al. 2009

Magnetic Resonance in Med

View full text Add to dashboard Cite

show abstract

“…In another study, Fe 3 O 4 contrast agents were coated by polyaspartic acid and applied for in vivo targeting of tumor xenografts to provide both MRI and PET images. [784] Subsequent to their surface coating, they were labeled with 64 cu radionuclides and DOTA stabilizing material. RGD peptides were also employed to specifically target integrin (α v β 3 ).…”

Section: Positron Emission Tomographymentioning

confidence: 99%

Synthesis, Functionalization, and Design of Magnetic Nanoparticles for Theranostic Applications

Mosayebi

Kiyasatfar

Laurent

2017

Adv Healthcare Materials

203

171

View full text Add to dashboard Cite

In order to translate nanotechnology into medical practice, magnetic nanoparticles (MNPs) have been presented as a class of non‐invasive nanomaterials for numerous biomedical applications. In particular, MNPs have opened a door for simultaneous diagnosis and brisk treatment of diseases in the form of theranostic agents. This review highlights the recent advances in preparation and utilization of MNPs from the synthesis and functionalization steps to the final design consideration in evading the body immune system for therapeutic and diagnostic applications with addressing the most recent examples of the literature in each section. This study provides a conceptual framework of a wide range of synthetic routes classified mainly as wet chemistry, state‐of‐the‐art microfluidic reactors, and biogenic routes, along with the most popular coating materials to stabilize resultant MNPs. Additionally, key aspects of prolonging the half‐life of MNPs via overcoming the sequential biological barriers are covered through unraveling the biophysical interactions at the bio–nano interface and giving a set of criteria to efficiently modulate MNPs' physicochemical properties. Furthermore, concepts of passive and active targeting for successful cell internalization, by respectively exploiting the unique properties of cancers and novel targeting ligands are described in detail. Finally, this study extensively covers the recent developments in magnetic drug targeting and hyperthermia as therapeutic applications of MNPs. In addition, multi‐modal imaging via fusion of magnetic resonance imaging, and also innovative magnetic particle imaging with other imaging techniques for early diagnosis of diseases are extensively provided.

show abstract

“…The unique qualities of nanoparticles described above make them superior in many ways to traditional low molecular weight MRI contrast agents and PET probes [88]. Compared to gadolinium-based MRI contrast agents, nanoparticle MRI contrast agents circulate in the blood for longer periods of time, offer greater sensitivity, and may produce fewer side-effects [89].…”

Section: Nanoparticle-based Mri and Mr/pet Imaging Contrast Agentsmentioning

confidence: 99%

Engineering imaging probes and molecular machines for nanomedicine

Tong

Cradick

et al. 2012

Sci. China Life Sci.

View full text Add to dashboard Cite

Nanomedicine is an emerging field that integrates nanotechnology, biomolecular engineering, life sciences and medicine; it is expected to produce major breakthroughs in medical diagnostics and therapeutics. Due to the size-compatibility of nano-scale structures and devices with proteins and nucleic acids, the design, synthesis and application of nanoprobes, nanocarriers and nanomachines provide unprecedented opportunities for achieving a better control of biological processes, and drastic improvements in disease detection, therapy, and prevention. Recent advances in nanomedicine include the development of functional nanoparticle based molecular imaging probes, nano-structured materials as drug/gene carriers for in vivo delivery, and engineered molecular machines for treating single-gene disorders. This review focuses on the development of molecular imaging probes and engineered nucleases for nanomedicine, including quantum dot bioconjugates, quantum dot-fluorescent protein FRET probes, molecular beacons, magnetic and gold nanoparticle based imaging contrast agents, and the design and validation of zinc finger nucleases (ZFNs) and TAL effector nucleases (TALENs) for gene targeting. The challenges in translating nanomedicine approaches to clinical applications are discussed. Nanomedicine is an emerging field that integrates nanotechnology, biomolecular engineering, biology, and medicine [1]. It focuses on the development of engineered nano-scale (1100 nm) materials, structures and devices for better diagnostics and highly specific medical intervention in curing disease or repairing damaged tissues. As a basis for nanomedicine, nanotechnology is the science, engineering, and technology related to the understanding and control of matter at the nano-scale, and the development of materials, devices, and systems that have novel properties and functions due to their nano-scale dimensions or components. Nanotechnology also provides new abilities to measure, control and manipulate matter (including soft matter) at the nano-scale what was unthinkable with conventional tools. Owing to the size-compatibility of nano-scale structures with proteins and nucleic acids in living cells, nanomedicine approaches have the potential to provide unprecedented opportunities for achieving a better control of biological processes, and drastic improvements in disease detection, therapy, and prevention, thus revolutionizing medicine. Over the last ten years or so, significant efforts have been made in the US, China, Europe and elsewhere to develop nanomedicine. For example, the US National Institutes of Health has developed a nanomedicine centers network, and invested a significant amount of research funding to nanomedicine development. Just in FY 2009 (Oct. 1, 2008Sept. 30, 2009, the total NIH funding in nanotechnology/ nanoscience projects was more than 410 million US dollars. SPECIAL TOPIC

show abstract

PET/MRI Dual-Modality Tumor Imaging Using Arginine-Glycine-Aspartic (RGD)–Conjugated Radiolabeled Iron Oxide Nanoparticles

Cited by 501 publications

References 28 publications

Superparamagnetic iron oxide nanoparticles as a dual imaging probe for targeting hepatocytes in vivo

Superparamagnetic iron oxide nanoparticles as a dual imaging probe for targeting hepatocytes in vivo

Synthesis, Functionalization, and Design of Magnetic Nanoparticles for Theranostic Applications

Engineering imaging probes and molecular machines for nanomedicine

Contact Info

Product

Resources

About